U
EVOK

UBS’s Evoke Pharma EVOK Stock Holding History

UBS’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1K Sell
2
-3
-60% -$2.9K ﹤0.01% 10148
2014
Q2 		$6K Sell
5
-4
-44% -$4.59K ﹤0.01% 9336
2014
Q1 		$11K Buy
9
+3
+50% +$4.28K ﹤0.01% 8786
2013
Q4 		$6K Buy
+6
New +$8.6K ﹤0.01% 9425

Other funds holding EVOK

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS's EVOK Position: Q3 2014 in Review

UBS reduced its Evoke Pharma (EVOK) stake by 60% in Q3 2014, selling an estimated $2.9K and leaving 2 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #10148.

UBS first reported a position in EVOK in Q4 2013 and has held it in 4 quarters since. The position peaked at $11K in Q1 2014. 11 funds tracked by Wall St. Rank hold EVOK as of Q3 2014.

  • UBS held 2 shares of Evoke Pharma worth $1K as of Q3 2014.
  • UBS sold 3 Evoke Pharma shares in Q3 2014, an estimated $2.9K.
  • Evoke Pharma made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10148 holding.
  • UBS first reported a position in Evoke Pharma in Q4 2013 and has held it in 4 quarters since.
  • UBS's Evoke Pharma position peaked at $11K in Q1 2014.
  • 11 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.